EA201691252A1 - Соединения индазола в качестве агонистов 5-ht-рецептора - Google Patents

Соединения индазола в качестве агонистов 5-ht-рецептора

Info

Publication number
EA201691252A1
EA201691252A1 EA201691252A EA201691252A EA201691252A1 EA 201691252 A1 EA201691252 A1 EA 201691252A1 EA 201691252 A EA201691252 A EA 201691252A EA 201691252 A EA201691252 A EA 201691252A EA 201691252 A1 EA201691252 A1 EA 201691252A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
indasol
receptor agonists
relates
agonists
Prior art date
Application number
EA201691252A
Other languages
English (en)
Other versions
EA029951B1 (ru
Inventor
Рамакришна Нироджи
Абдул Рашид Мохаммед
Анил Карбхари Схинде
Шанкар Редди Гаггинапалли
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA201691252A1 publication Critical patent/EA201691252A1/ru
Publication of EA029951B1 publication Critical patent/EA029951B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым соединениям индазола формулы (I), в том числе к их стереоизомерам и их фармацевтически приемлемым солям. Это изобретение также относится к способам получения таких соединений и к фармацевтическим композициям, включающим такие соединения. Соединения этого изобретения применяют при лечении различных расстройств, которые связаны с агонистами 5-гидрокситриптаминовых рецепторов 4-го типа (5-НТ).
EA201691252A 2013-12-16 2014-02-24 Соединения индазола в качестве агонистов 5-ht-рецептора EA029951B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5852CH2013 2013-12-16
PCT/IN2014/000116 WO2015092804A1 (en) 2013-12-16 2014-02-24 Indazole compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
EA201691252A1 true EA201691252A1 (ru) 2016-12-30
EA029951B1 EA029951B1 (ru) 2018-06-29

Family

ID=50736125

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691252A EA029951B1 (ru) 2013-12-16 2014-02-24 Соединения индазола в качестве агонистов 5-ht-рецептора

Country Status (17)

Country Link
US (1) US9951045B2 (ru)
EP (1) EP3099675B1 (ru)
JP (1) JP6161823B2 (ru)
KR (1) KR101824154B1 (ru)
CN (1) CN105873920B (ru)
AP (1) AP2016009253A0 (ru)
AU (1) AU2014369085B2 (ru)
BR (1) BR112016013974B1 (ru)
CA (1) CA2932428C (ru)
DK (1) DK3099675T3 (ru)
EA (1) EA029951B1 (ru)
ES (1) ES2668873T3 (ru)
IL (1) IL245948B (ru)
MX (1) MX368017B (ru)
NZ (1) NZ720879A (ru)
SG (1) SG11201604849YA (ru)
WO (1) WO2015092804A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ728918A (en) 2014-08-16 2018-05-25 Suven Life Sciences Ltd Process for large scale production of 1-isopropyl-3-{ 5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl} -1h-indazole oxalate
ES2734734T3 (es) * 2015-02-13 2019-12-11 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor 5-HT4
JP6900028B2 (ja) * 2017-03-29 2021-07-07 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤
EP3628660A1 (en) * 2018-09-28 2020-04-01 Université de Caen Normandie Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases
EP4317141A1 (en) 2022-08-04 2024-02-07 Curia Spain S.A.U. Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708174A (en) 1992-03-12 1998-01-13 Smithkline Beecham P.L.C. Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
ES2248616T3 (es) 2001-10-22 2006-03-16 Pfizer Inc. Compuestos imidazopiridina como moduladores del receptor 5-ht4.
WO2004094418A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
EP1689742B1 (en) 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
ATE457309T1 (de) * 2003-12-23 2010-02-15 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
ATE469897T1 (de) * 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
JP4970290B2 (ja) 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
WO2011099305A1 (en) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
CN102762554A (zh) 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
US9079894B2 (en) * 2011-09-19 2015-07-14 Suven Life Sciences Ltd Heteroaryl compounds as 5-HT4 receptor ligands

Also Published As

Publication number Publication date
DK3099675T3 (en) 2018-05-22
CA2932428A1 (en) 2015-06-25
IL245948A0 (en) 2016-08-02
MX2016007857A (es) 2016-09-07
AP2016009253A0 (en) 2016-06-30
NZ720879A (en) 2017-05-26
JP6161823B2 (ja) 2017-07-12
SG11201604849YA (en) 2016-07-28
AU2014369085A1 (en) 2016-06-30
AU2014369085B2 (en) 2017-02-23
WO2015092804A1 (en) 2015-06-25
CN105873920A (zh) 2016-08-17
KR101824154B1 (ko) 2018-03-14
US9951045B2 (en) 2018-04-24
US20160311797A1 (en) 2016-10-27
BR112016013974A2 (pt) 2017-08-08
EP3099675B1 (en) 2018-02-14
ES2668873T3 (es) 2018-05-22
JP2016540796A (ja) 2016-12-28
CN105873920B (zh) 2018-06-08
EP3099675A1 (en) 2016-12-07
EA029951B1 (ru) 2018-06-29
CA2932428C (en) 2017-10-24
BR112016013974B1 (pt) 2022-11-22
BR112016013974A8 (pt) 2018-01-30
MX368017B (es) 2019-09-13
IL245948B (en) 2019-08-29
KR20160075832A (ko) 2016-06-29

Similar Documents

Publication Publication Date Title
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201691302A1 (ru) Новые гетероциклические соединения
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201700042A1 (ru) Соединения имидазопиридазина
EA201690888A1 (ru) Новые гетероциклические соединения
EA201600434A1 (ru) Применение производных бензимидазолпролина
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
PH12017501736A1 (en) Indole derivatives
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
EA201791398A1 (ru) Производные фумагиллола
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
NZ720304A (en) Amide derivatives for gpr119 agonist